RAAS Inhibitors and Risk of Covid-19
Fabio Angeli, Paolo Verdecchia, Gianpaolo Reboldi
Abstract
tent with a drug-induced process 3 but rather with the patients' underlying disease.Treatment with givosiran was associated with small increases in creatinine (0.07 mg per deciliter at 3 months) in the overall trial population, changes that were mainly reversible.Some patients with preexisting renal disease had reductions in renal function that stabilized with ongoing administration of givosiran.However, consistent with labeling, monitoring of renal function during givosiran treatment is recommended as clinically indicated.
Topics & Concepts
Renal functionMedicineCreatinineCoronavirus disease 2019 (COVID-19)DiseasePopulationImpaired renal functionInternal medicineIntensive care medicineUrologyInfectious disease (medical specialty)Environmental healthCOVID-19 Clinical Research StudiesCardiac electrophysiology and arrhythmiasCardiac Imaging and Diagnostics